Search the Newsreel

Citizens reiterates Immix Biopharma stock rating on pipeline progress

Citizens reiterated a "Market Outperform" rating and a $23.00 price target for Immix Biopharma (NASDAQ:IMMX), citing strong pipeline progress and potential for significant upside despite recent financial losses and an "overvalued" assessment by InvestingPro. The firm highlighted upcoming top-line results for NXC-201 in September …

Janus Henderson Group (IMMX) discloses 9.78M-share beneficial stake in Immix Biopharma

Janus Henderson Group Ltd., through its investment adviser subsidiaries, has reported a beneficial ownership of 9,783,192 shares of Immix Biopharma, Inc. common stock, representing 14.0% of the class. These shares are held in client accounts, known as Managed Portfolios, where Janus Henderson's asset managers …

Immix Biopharma Q3 EPS Estimate Lowered by HC Wainwright

HC Wainwright has lowered its Q3 2026 EPS estimate for Immix Biopharma (NASDAQ:IMMX) to a loss of $0.17 per share, down from a previous forecast of $0.14 loss, while maintaining a "Buy" rating and a $25 price target. This revision follows Immix Biopharma reporting …

HC Wainwright Estimates Immix Biopharma FY2027 Earnings

HC Wainwright forecasts Immix Biopharma (NASDAQ: IMMX) to report a loss of $0.20 per share for FY2027, maintaining a "Buy" rating and a $25 price target. This contrasts with the current consensus estimate of a $0.69 loss per share. The company recently reported a …

Immix Biopharma publishes corporate presentation on NXC-201 BCMA CAR-T in relapsed/refractory AL amyloidosis

Immix Biopharma has published a corporate presentation detailing its lead program, NXC-201 BCMA CAR-T, for relapsed or refractory AL amyloidosis. The presentation highlights a 95% complete response rate for NXC-201 from its NEXICART-2 U.S. phase 1/2 trial, which has completed enrollment with 45 patients. …

Immix Biopharma, Inc. Stock 12‑Month Price Target Cut to $20.44, Implies 102% Upside

Immix Biopharma, Inc. (IMMX) has seen its average 12-month price target adjusted down slightly from $20.56 to $20.44 by 8 analysts. Despite the minor cut, the new target still implies a significant 102% potential upside from its Aug. 10 closing price. The consensus rating …

Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating

Morgan Stanley has adjusted its price target for Immix Biopharma (IMMX) to $19, down from $20, while maintaining an Overweight rating on the stock. This update comes after the company recently reported its earnings results for the second quarter and six months ended June …

H.C. Wainwright raises Immix Biopharma price target to $25 By Investing.com

H.C. Wainwright has increased its price target for Immix Biopharma (NASDAQ:IMMX) to $25 from $20, reiterating a Buy rating, despite the company posting a wider net loss for Q2 2026 than previously estimated. The firm cited Immix's strong cash position of $234.2 million, providing …

H.C. Wainwright raises Immix Biopharma price target to $25

H.C. Wainwright has raised its price target for Immix Biopharma (NASDAQ:IMMX) to $25 from $20, while reiterating a Buy rating, citing an advanced discounted cash flow valuation and consideration of ex-U.S. sales from NXC-201. The firm updated its earnings estimates, now projecting a net …

Immix Biopharma (NASDAQ:IMMX) Stock Price Down 6.7% - Here's What Happened

Immix Biopharma (NASDAQ: IMMX) saw its stock price drop by 6.7% to $9.39 during midday trading on Friday, with trading volume significantly lower than average. Despite this decline, analyst sentiment remains largely positive, with a "Moderate Buy" consensus and an average price target of …

Immix Biopharma (NASDAQ:IMMX) Announces Quarterly Earnings Results

Immix Biopharma (NASDAQ:IMMX) announced its quarterly earnings, reporting an EPS of ($0.18), which slightly missed the consensus estimate of ($0.17). Following the news, shares dropped 3.4% to $9.72, significantly below the average analyst target price of $20.71. Despite the earnings miss, the company holds …

Immix Biopharma (NASDAQ: IMMX) ends Q2 2026 with $232.1M in cash

Immix Biopharma Q2 FY26 net loss widens to USD 11.56 million; G&A expense more than doubled to USD 7.12 million

Immix Biopharma reported a widened net loss of USD 11.56 million for Q2 FY26, compared to USD 6.62 million in the previous year. This increase was primarily driven by general and administrative expenses more than doubling to USD 7.12 million due to higher compensation …

Immix Biopharma Inc (IMMX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Immix Biopharma (IMMX) Projected to Post Quarterly Earnings on Friday

IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS) has launched an investigation into Immix Biopharma, Inc. (NASDAQ: IMMX) following revelations about the company's former Chief Medical Officer, Richard Graydon, who was allegedly a fugitive named Ronald L. Fischer. Fischer had disappeared during a rape trial in …

ImmixBio plans one-on-one investor meetings in New York Sept. 14-16

Immix Biopharma (Nasdaq: IMMX) announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference from September 14-16, 2026, where it will host one-on-one investor meetings. The company will discuss its lead AL Amyloidosis CAR-T candidate, NXC-201, which has received FDA Breakthrough Therapy, …

Immix Biopharma Announces Participation in Morgan Stanley 24th Annual Global Healthcare Conference and Institutional Investor Meetings

Immix Biopharma (IMMX) announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference from September 14-16, 2026, where it will host meetings with institutional investors. The company, a leader in treating relapsed/refractory AL Amyloidosis, will discuss its lead CAR-T cell therapy, NXC-201, …

IMMX INVESTIGATION: Immix Biopharma Investors Who Lost Money After Reports About Its Former CMO Should Contact Block & Leviton

Block & Leviton is investigating Immix Biopharma (NASDAQ:IMMX) for potential securities law violations after reports surfaced that a former executive, identified as "Richard Graydon," was allegedly a fugitive operating under a false identity. Immix Biopharma shares fell approximately 10.83% on the day this report …

Immix Biopharma Inc (IMMX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Immix Biopharma Inc (IMMX), detailing its support, resistance levels, and the readings of various technical indicators and moving averages. It presents a summary of "Buy," "Sell," and "Neutral" signals for different indicators and moving averages, offering insights …

IMMX|Immix Biopharma Inc|Price:8.690|Chg%:+0.170

This article provides detailed market trends and financial analysis for Immix Biopharma Inc (IMMX), including real-time quotes, key figures, and analyst ratings. It highlights that seven analysts currently rate IMMX as "Buy" with a target price of $20.714, representing a 143.13% upside. The company …

Immix Biopharma Inc (IMMX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of dividend and stock split information for Immix Biopharma Inc (IMMX). It notes that the company has not distributed any dividends over the past five years. The page also presents current stock data, including its market cap and recent …

Immix Biopharma, Inc. Revenue Breakdown – NASDAQ:IMMX

This article provides an overview of Immix Biopharma, Inc. (NASDAQ: IMMX), focusing on its revenue breakdown and financial data available on TradingView. It highlights the company's financial segment performance and regional contributions, emphasizing that this data is sourced from ICE Data Services and FactSet. …

Immix Biopharma Inc (IMMX) Income Statement

Immix Biopharma Inc (IMMX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Immix Biopharma Inc (IMMX), listing major individual and institutional holders, their proportions, and changes in their holdings. It also categorizes shareholders by type and provides historical institutional shareholding data and related ETF information.

Immix Biopharma Inc (IMMX) Institutional Confidence

This article provides details on the institutional confidence in Immix Biopharma Inc (IMMX), listing major shareholders and their holdings. Key institutional investors include Hsu (Jason), Janus Henderson Investors, GKCC, LLC, and Eventide Asset Management, LLC. Noteworthy changes in holdings include significant increases from Marshall …

Immix Biopharma, Inc. At-The-Market Equity Offering · $5M raised · (2023)

Immix Biopharma Inc. raised $5 million through an At-The-Market Equity Offering announced on June 14, 2023. The biopharmaceutical company is developing NXC-201, a one-time CAR-T therapy for AL Amyloidosis, aimed at re-engineering the immune system to fight diseased cells. This funding is described as …

Needham Initiates Immix Biopharma(IMMX.US) With Buy Rating, Announces Target Price $21

Needham has initiated coverage on Immix Biopharma (IMMX.US) with a Buy rating. The firm has set a target price of $21 for the company's stock. This initiation suggests a positive outlook from Needham on Immix Biopharma's future performance.

Immix Biopharma Investigated by the Portnoy Law Firm

The Portnoy Law Firm has launched an investigation into Immix Biopharma (NASDAQ: IMMX) for potential securities fraud. This follows revelations that an executive, "Richard Graydon," was allegedly Ronald Fischer, a Rhode Island fugitive operating under a false identity. Immix's share price dropped by approximately …

IMMX INVESTOR ALERT: Holzer & Holzer, LLC Announces Investigation of Immix Biopharma, Inc.

Holzer & Holzer, LLC has announced an investigation into Immix Biopharma, Inc. (NASDAQ: IMMX) following a significant drop in the company's stock price. The investigation stems from Immix's disclosure that it terminated its Chief Medical Officer after news reports revealed the CMO was using …

Immix Biopharma Stock Drops Significantly On News of Chief Medical Officer Arrest - IMMX Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Potential Securities Fraud Claims

Kehoe Law Firm, P.C. is investigating potential securities fraud claims against Immix Biopharma, Inc. after its stock dropped significantly following reports that one of its executives, Ronald Fischer, was arrested and identified as a long-sought fugitive. Fischer, the company's Chief Medical Officer, had disappeared …

IMMX ALERT: Immix Biopharma Investigated for Securities Fraud Violations by Block & Leviton; Investors Should Contact the Firm

Block & Leviton is investigating Immix Biopharma (Nasdaq: IMMX) for potential securities law violations after a former executive, "Richard Graydon," was allegedly identified as a most-wanted fugitive, Ronald Fischer, operating under a false identity. Although Immix stated the termination was unrelated to his activities …

Immix Biopharma stock tumbles amid fugitive CMO report

Immix Biopharma's stock fell 13% after a report revealed that its Chief Medical Officer, hired under the name Richard Graydon, was allegedly Ronald Fischer, a Rhode Island fugitive wanted for sexual assault since 2005. Fischer was recently arrested on a sailboat. The company terminated …